Using Biomarkers to Detect the Temporal Trend of Subclinical Cardiotoxicity in Patients with Breast Cancer Treated with Anthracyclines and Her2+ Antagonists

Vol VI Issue I
DOI:10.5083/ejcm20424884.178 , Cite or Link Using DOI
Creating a Digital Object Identifier Link

A digital object identifier (DOI) can be used to cite and link to electronic documents. A DOI is guaranteed never to change, so you can use it to link permanently to electronic documents.

To find a document using a DOI

  1. Copy the DOI of the document you want to open.
    The correct format for citing a DOI is as follows: doi:10.1016/S0140-6736(08)61345-8
  2. Open the following DOI site in your browser:
  3. Enter the entire DOI citation in the text box provided, and then click Go.
    The document that matches the DOI citation will display in your browser window.

The DOI scheme is administered by the International DOI Foundation. Many of the world's leading publishers have come together to build a DOI-based document linking scheme known as CrossRef.

Wendy Bottinor, Natalie Kelsey, Elizabeth C Riley, John Craycroft, Carrie G Lenneman, Maiying Kong


Background: Standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive (HER2+) breast cancer often involves HER2 antagonism and anthracyclines. Anthracyclines and HER2 antagonists are associated with cardiotoxicity and cardiac screening is suggested. The optimal strategy for cardiac monitoring is not definitively established and the potential role of biomarkers to detect subclinical cardiotoxicity is an active area of interest within the field of cardio-oncology.

Methods: This single center retrospective cohort analysis, examined the role of troponin I (Tp I) to detect subclinical cardiotoxicity and predict subsequent cardiovascular dysfunction in patients undergoing treatment for HER2+ breast cancer treated with combination trastuzumab and pertuzumab therapy. Subjects were identified by review of cardio-oncology and medical oncology clinical registries. Demographic and clinical data were obtained through chart review. Tp I absolute values and temporal trends, and subsequent decline in left ventricular ejection fraction or development of symptomatic heart failure were evaluated and compared for different chemotherapeutic regimens.

Results: The incidence of Tp I elevation was significantly higher in patients treated with both anthracycline and HER2 antagonism when compared to patients treated with anthracycline or HER2 antagonism alone. In patients treated with both anthracycline and HER2 antagonism (either trastuzumab alone or in combination with pertuzumab), Tp I levels became positive (greater than 0.03 ng/mL) after the completion anthracycline therapy and 3.8 + 1.93 infusions of anti-HER2 therapy. The average peak Tp I was 0.104 + 0.05. Resolution of Tp I elevation occurred by infusion 14 + 1.94.

Conclusions: Patients treated with a combination of anthracycline and HER2 antagonism, demonstrated elevated Tp I values with peak Tp I occurring after completion of anthracyclines and approximately 7 infusions of HER2 antagonist therapy